Daily Roundup

TBN.ASX ENN.ASX ATX.ASX BUB.ASX 3DP.ASX

Tamboran Resources has completed its acquisition of Falcon Oil & Gas Limited, significantly expanding its footprint in the Beetaloo Basin. The deal, which received court approval, involved issuing 6,537,503 shares to Falcon shareholders and positions Tamboran as the largest acreage holder in the region with 2.8 million net prospective acres. The combined entity now carries a pro forma market capitalization of approximately US$1.2 billion, bolstering its exploration and production capabilities.

Over at Elanor Investors Group, plans have shifted. The company announced that its acquisition of Firmus Capital, a Singapore-based real estate investment manager, won't be moving forward due to regulatory approval delays. Rockworth Capital Partners will retain its 17.9 million ENN securities as a result. Elanor has submitted to the ASX for trading recommencement, subject to meeting certain conditions, and signaled it will continue exploring future acquisition opportunities with Rockworth.

Amplia Therapeutics is making headway in its fight against pancreatic cancer. The company's ACCENT trial has delivered encouraging results for narmafotinib, showing a 36% confirmed objective response rate and median progression-free survival of 7.7 months when combined with standard chemotherapy. However, the company discontinued its AMPLICITY trial after observing high toxicity with a more aggressive chemotherapy regimen. The FDA has already provided positive feedback on Amplia's planned registration-enabling study design. To fuel these efforts, the biotech firm raised $27.5 million and is now exploring new combination approaches alongside its lead program.

Bubs Australia is navigating a challenging landscape but maintaining underlying momentum. The infant nutrition company expects FY26 revenue between $105 million and $115 million, with reported EBITDA between -$2 million and +$2 million, though underlying EBITDA should land between $4 million and $8 million. The company has faced headwinds from evolving regulatory requirements, product availability constraints, geopolitical disruptions, and increased freight costs. On the bright side, FDA engagement remains positive and is progressing toward its final stages, while Bubs maintains a strong balance sheet and liquidity position as it pushes forward with USA expansion.

Pointerra has landed a meaningful contract with Origin Energy. The software company secured a multi-year Master Services Agreement to deploy its Pointerra3D platform for monitoring approximately 750km of Origin's gas transmission pipeline in Queensland. The three-year initial contract is valued at A$0.7 million and can be extended for up to five years, providing visibility into contracted revenue. The platform will handle automated threat detection, compliance reporting, and change analysis, positioning Pointerra for potential expansion into additional asset classes within Origin's broader portfolio.